- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- April 2024
- 193 Pages
Global
From €5269EUR$5,450USD£4,528GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 85 Pages
North America
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 90 Pages
Europe
From €4592EUR$4,750USD£3,947GBP
- Report
- April 2023
- 80 Pages
Asia Pacific
From €4592EUR$4,750USD£3,947GBP
- Report
- April 2023
- 87 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,202GBP
Remifentanil is an opioid analgesic drug used in anesthetic drugs. It is a short-acting, synthetic opioid that is used to provide sedation and analgesia during medical procedures. It is a mu-opioid receptor agonist, meaning it binds to the mu-opioid receptor in the brain to produce its effects. Remifentanil is used in combination with other anesthetic drugs to provide a balanced anesthetic effect. It is also used to provide sedation and analgesia during labor and delivery. Remifentanil is a fast-acting drug, with a rapid onset of action and a short duration of action. It is metabolized quickly by the body, making it a safe and effective option for anesthetic drugs.
Some companies in the Remifentanil market include Mylan, Fresenius Kabi, Hospira, and Teva Pharmaceuticals. Show Less Read more